Renovaro appoints Nathen Fuentes as CFO; removes interim CFO Simon Tarsh

Lunai Bioworks Inc.

Nathen Fuentes, age 42, appointed CFO effective January 6, 2025; previously CFO at Telomir Pharmaceuticals (Sep 2023 – Jun 2024).
Base salary of $280,000 per year; performance bonus up to $40,000 annually, pro-rated for 2025.
Equity incentive grant of 250,000 stock options vesting quarterly over eight quarters; discretionary equity grant on first anniversary.
If terminated without cause or for good reason: six months base salary, COBRA reimbursement for 6 months, accelerated vesting of time-based awards.
Simon Tarsh removed as Interim CFO in connection with Fuentes' appointment.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed (interim)

Simon Tarsh

Interim Chief Financial Officer

LNAI · Lunai Bioworks Inc.

Effective: 2025-01-06
Successor: Nathen Fuentes
Filed: January 13, 2025, 6:59 PM ET

In connection with Mr. Fuentes’ appointment as Chief Financial Officer, Simon Tarsh was removed as Interim Chief Financial Officer of the Company.

Appointed

Nathen Fuentes

Chief Financial Officer

LNAI · Lunai Bioworks Inc.

Effective: 2025-01-06
Filed: January 13, 2025, 6:59 PM ET

Effective January 6, 2025, the board of directors (the “ Board ”) of Renovaro Inc. (the “ Company ” or “ Renovaro ”) appointed Nathen Fuentes, age 42, as Chief Financial Officer of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Simon Tarsh was removed as Interim Chief Financial Officer at Lunai Bioworks Inc..

Action: removed
Role: Interim Chief Financial Officer

Exact text from the filing

In connection with Mr. Fuentes’ appointment as Chief Financial Officer, Simon Tarsh was removed as Interim Chief Financial Officer of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Nathen Fuentes was appointed as Chief Financial Officer at Lunai Bioworks Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

Effective January 6, 2025, the board of directors (the “ Board ”) of Renovaro Inc. (the “ Company ” or “ Renovaro ”) appointed Nathen Fuentes, age 42, as Chief Financial Officer of the Company.

View on SEC.gov

Lunai Bioworks Inc. filing history →

Source: SEC EDGAR

accession 0001731122-25-000067

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.